Biography
Since joining the faculty at Stanford in 2007, Dr. Iagaru has received several awards including the Society of Nuclear Medicine (SNM) 2009 Image of the Year Award; AuntMinnie 2016 Best Radiology Image, American College of Nuclear Medicine (ACNM) Mid-Winter Conference 2010 Best Essay Award; 2009, 2014 and 2015 Western Regional SNM Scientist Award; 2011 SNM Nuclear Oncology Council Young Investigator Award; the 2020 Sanjiv Sam Gambhir Distinguished Scientist Award, Western Regional SNM and the 2022 Sanjiv Sam Gambhir Trailblazer Award, SNMMI. Dr. Iagaru published more than 210 papers in peer-reviewed journals, as well as 9 book chapters and 1 book.
Professional Summary
Education & Certifications
- Residency: University of Southern California Keck School of Medicine (2005) CA
- Internship: Graduate Hospital (Closed) (2004) PA
- Residency: Stanford University Medical Center (2006) CA
- Fellowship: Stanford University Medical Center (2007) CA
- Board Certification: American Board of Nuclear Medicine, Nuclear Medicine (2006)
- Medical Education: Carol Davila University of Medicine (2000) Romania
Honors & Awards
- Alavi-Mandell Award, Society of Nuclear Medicine and Molecular Imaging (2008)
- Alavi-Mandell Award, Society of Nuclear Medicine and Molecular Imaging (2009)
- Alavi-Mandell Award, Society of Nuclear Medicine and Molecular Imaging (2010)
- Best Essay Award, American College of Nuclear Medicine (2010)
- Best Essay Award, American College of Nuclear Medicine (2011)
- Best Essay Award, American College of Nuclear Physicians (2008)
- Clinician Educator of the Year Award, Stanford Radiology Residency Program (2008)
- Clinician of the Year, Department of Radiology, Stanford University (2018)
- Developmental Cancer Research Award, Stanford Cancer Center (2009)
- Editor’s Recognition Award, Clinical Nuclear Medicine (2016)
- Fellow Award, American College of Nuclear Medicine (2013)
- Image of the Year, Society of Nuclear Medicine and Molecular Imaging (2009)
- Norman D. Poe Memorial Scholarship Award, Western Regional Society of Nuclear Medicine (2009)
- Norman D. Poe Memorial Scholarship Award, Western Regional Society of Nuclear Medicine (2014)
- Norman D. Poe Memorial Scholarship Award, Western Regional Society of Nuclear Medicine (2015)
- Norman D. Poe Memorial Scholarship Award, Western Regional Society of Nuclear Medicine (2017)
- Nuclear Oncology Council Young Investigator Award - Second Place, Society of Nuclear Medicine and Molecular Imaging (2011)
- Radiopharmaceutical Sciences Council Travel Grant, Society of Nuclear Medicine and Molecular Imaging (2011)
- The Saniv Sam Gambhir Trailblazer Award, Society of Nuclear Medicine and Molecular Imaging (2022)
- The Sanjiv Sam Gambhir Distinguished Scientist Award, Western Regional SNM (2020)
- Travel Grant, American College of Nuclear Physicians (2007)
- Young Professionals Tournament - First Place, SNMMI & Chinese Society of Nuclear Medicine Joint Meeting (2011)
Memberships
- Board of Directors, American Board of Nuclear Medicine (2016 - 2022)
- Member, ACGME, Nuclear Medicine RRC (2019 - Present)
- Member, National Comprehensive Cancer Network Thyroid Cancer Panel (2013 - Present)
- Board of Directors, PET Center of Excellence, Society of Nuclear Medicine and Molecular Imaging (2013 - 2015)
- Chair, Targeted Radionuclide Therapy Working Group, Society of Nuclear Medicine and Molecular Imaging (2012 - 2016)
- Co-Chair, Outreach Committee, Society of Nuclear Medicine and Molecular Imaging (2011 - 2016)
- Co-Chair, PET/MRI Task Force, Society of Nuclear Medicine and Molecular Imaging (2013 - 2015)
- Co-Chair, Oncology Working Group, Society of Nuclear Medicine and Molecular Imaging (2013 - 2014)
Administrative Appointments
- Member, Department of Radiology Education Committee (2009 - 2019)
- Member, Clinical Radiation Safety Committee (2009 - Present)
- Member, Radioactive Drug Research Committee (2009 - Present)
- Member, Scientific Review Committee, Stanford Cancer Institute (2012 - Present)
- Program Director, Nuclear Medicine Residency Program (2011 - 2019)
Publications
-
FDG PET-CT demonstration of Sjogren's sialoadenitis
Jadvar, H., Bonyadlou, S., Iagaru, A., & Colletti, P. M. (2005). FDG PET-CT demonstration of Sjogren's sialoadenitis. CLINICAL NUCLEAR MEDICINE, 30(10), 698–699. -
Failed atrial septal defect repair versus pulmonary hypertension with right ventricular failure
Iagaru, A., Wassef, H., & Henderson, R. (2005). Failed atrial septal defect repair versus pulmonary hypertension with right ventricular failure. CLINICAL NUCLEAR MEDICINE, 30(11), 767–768. -
-
-
Merkel cell carcinoma: Is there a role for 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography?
Iagaru, A., Quon, A., McDougall, I. R., & Gambhir, S. S. (2006). Merkel cell carcinoma: Is there a role for 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography? MOLECULAR IMAGING AND BIOLOGY, 8(4), 212–17. -
2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer
Iagaru, A., Masamed, R., Singer, P. A., & Conti, P. S. (2006). 2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer. MOLECULAR IMAGING AND BIOLOGY, 8(5), 309–314. -
F-18FDG PET imaging of urinary bladder oat cell carcinoma with widespread osseous metastases
Iagaru, A., Gamie, S., & Segall, G. (2006). F-18FDG PET imaging of urinary bladder oat cell carcinoma with widespread osseous metastases. CLINICAL NUCLEAR MEDICINE, 31(8), 476–78. -
PET/CT follow-up in nonossifying fibroma
Iagaru, A., & Henderson, R. (2006). PET/CT follow-up in nonossifying fibroma. AMERICAN JOURNAL OF ROENTGENOLOGY, 187(3), 830–832. -
Demonstration of an ectopic mediastinal parathyroid adenoma on Tc-99m sestamibi myocardial perfusion scintigraphy
Iagaru, A., Hachamovitch, R., Colletti, P. M., & Wassef, H. (2006). Demonstration of an ectopic mediastinal parathyroid adenoma on Tc-99m sestamibi myocardial perfusion scintigraphy. JOURNAL OF NUCLEAR CARDIOLOGY, 13(5), 719–721. -
F-18-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas
Iagaru, A., Chawla, S., Menendez, L., & Conti, P. S. (2006). F-18-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas. NUCLEAR MEDICINE COMMUNICATIONS, 27(10), 795–802. -
2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma
Iagaru, A., Quon, A., Johnson, D., Gambhir, S. S., & McDougall, I. R. (2007). 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography/computed tomography in the management of melanoma. MOLECULAR IMAGING AND BIOLOGY, 9(1), 50–57. -
F-18FDG PET/CT evaluation of osseous and soft tissue sarcomas
Iagaru, A., Quon, A., McDougall, T. R., & Gambhir, S. S. (2006). F-18FDG PET/CT evaluation of osseous and soft tissue sarcomas. CLINICAL NUCLEAR MEDICINE, 31(12), 754–760. -
F-18FDG PET/CT demonstration of an adrenal metastasis in a patient with anaplastic thyroid cancer
Iagaru, A., & McDougall, I. R. (2007). F-18FDG PET/CT demonstration of an adrenal metastasis in a patient with anaplastic thyroid cancer. CLINICAL NUCLEAR MEDICINE, 32(1), 13–15. -
Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT
Iagaru, A., Masamed, R., Singer, P. A., & Conti, P. S. (2007). Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT. MOLECULAR IMAGING AND BIOLOGY, 9(2), 72–77. -
-
-
-
Breast MRI and F-18 FDG PET/CT in the management of breast cancer
Iagaru, A., Masamed, R., Keesara, S., & Conti, P. S. (2007). Breast MRI and F-18 FDG PET/CT in the management of breast cancer. ANNALS OF NUCLEAR MEDICINE, 21(1), 33–38. -
-
F-18 FDG PET/CT in the management of thyroid cancer
Iagaru, A., Kalinyak, J. E., & McDougall, I. R. (2007). F-18 FDG PET/CT in the management of thyroid cancer. CLINICAL NUCLEAR MEDICINE, 32(9), 690–95. -
-
-
F-18FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas
Iagaru, A., Masamed, R., Chawla, S. P., Menendez, L. R., Fedenko, A., & Conti, P. S. (2008). F-18FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas. CLINICAL NUCLEAR MEDICINE, 33(1), 8–13. -
Perspectives of molecular imaging and radioimmunotherapy in lymphoma
Iagaru, A., Goris, M. L., & Gambhir, S. S. (2008). Perspectives of molecular imaging and radioimmunotherapy in lymphoma. RADIOLOGIC CLINICS OF NORTH AMERICA, 46(2), 243–52. -
-
-
F-18-FDG PET/CT evaluation of patients with ovarian carcinoma
Iagaru, A. H., Mittra, E. S., McDougall, I. R., Quon, A., & Gambhir, S. S. (2008). F-18-FDG PET/CT evaluation of patients with ovarian carcinoma. NUCLEAR MEDICINE COMMUNICATIONS, 29(12), 1046–1051. -
F-18-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan?
Iagaru, A., Wang, Y., Mari, C., Quon, A., Goris, M. L., Horning, S., & Gambhir, S. S. (2008). F-18-FDG-PET/CT evaluation of response to treatment in lymphoma: when is the optimal time for the first re-evaluation scan? HELLENIC JOURNAL OF NUCLEAR MEDICINE, 11(3), 153–56. -
-
-
Incorporating Cone-beam CT into the Treatment Planning for Yttrium-90 Radioembolization
Louie, J. D., Kothary, N., Kuo, W. T., Hwang, G. L., Hofmann, L. V., Goris, M. L., … Sze, D. Y. (2009). Incorporating Cone-beam CT into the Treatment Planning for Yttrium-90 Radioembolization. JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 20(5), 606–13. -
I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma
Iagaru, A., Mittra, E. S., Ganjoo, K., Knox, S. J., & Goris, M. L. (2010). I-131-Tositumomab (BexxarA (R)) vs. Y-90-Ibritumomab (ZevalinA (R)) Therapy of Low-Grade Refractory/Relapsed Non-Hodgkin Lymphoma. MOLECULAR IMAGING AND BIOLOGY, 12(2), 198–203. -
-
-
F-18 FDG PET/CT Demonstration of Lymphohistiocytic Meningitis
Mansouri, M. A., & Iagaru, A. (2010). F-18 FDG PET/CT Demonstration of Lymphohistiocytic Meningitis. CLINICAL NUCLEAR MEDICINE, 35(8), 633–34. -
Current concepts and future directions in radioimmunotherapy.
Lin, F. I., & Iagaru, A. (2010). Current concepts and future directions in radioimmunotherapy. Current Drug Discovery Technologies, 7(4), 253–262. -
-
-
Prospective Evaluation of Tc-99m MDP Scintigraphy, F-18 NaF PET/CT, and F-18 FDG PET/CT for Detection of Skeletal Metastases
Iagaru, A., Mittra, E., Dick, D. W., & Gambhir, S. S. (2012). Prospective Evaluation of Tc-99m MDP Scintigraphy, F-18 NaF PET/CT, and F-18 FDG PET/CT for Detection of Skeletal Metastases. MOLECULAR IMAGING AND BIOLOGY, 14(2), 252–59. -
Pilot Pharmacokinetic and Dosimetric Studies of F-18-FPPRGD2: A PET Radiopharmaceutical Agent for Imaging alpha(v)beta(3) Integrin Levels
Mittra, E. S., Goris, M. L., Iagaru, A. H., Kardan, A., Burton, L., Berganos, R., … Gambhir, S. S. (2011). Pilot Pharmacokinetic and Dosimetric Studies of F-18-FPPRGD2: A PET Radiopharmaceutical Agent for Imaging alpha(v)beta(3) Integrin Levels. RADIOLOGY, 260(1), 182–91. -
-
-
-
-
Demonstration of peripheral nerve root involvement by non-Hodgkin's lymphoma on F-18-FDG PET/CT
Guo, H., Mosci, C., & Iagaru, A. (2012). Demonstration of peripheral nerve root involvement by non-Hodgkin's lymphoma on F-18-FDG PET/CT. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 39(4), 729–30. -
-
-
Validation that metabolic tumor volume predicts outcome in head-and-neck cancer.
Tang, C., Murphy, J. D., Khong, B., La, T. H., Kong, C., Fischbein, N. J., … Le, Q.-T. (2012). Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. International Journal of Radiation Oncology, Biology, Physics, 83(5), 1514–20. -
F-18-FDG PET/CT Demonstration of a Liver Metastasis in a Patient With Papillary Thyroid Cancer
Mosci, C., McDougall, I. R., Jeffrey, R. B., & Iagaru, A. (2012). F-18-FDG PET/CT Demonstration of a Liver Metastasis in a Patient With Papillary Thyroid Cancer. CLINICAL NUCLEAR MEDICINE, 37(9), E234–E236. -
Initial investigation of F-18-NaF PET/CT for identification of vertebral sites amenable to surgical revision after spinal fusion surgery
Quon, A., Dodd, R., Iagaru, A., de Abreu, M. R., Hennemann, S., Alves Neto, J. M., & Sprinz, C. (2012). Initial investigation of F-18-NaF PET/CT for identification of vertebral sites amenable to surgical revision after spinal fusion surgery. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 39(11), 1737–44. -
(18)F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge.
Iagaru, A. (2011). (18)F-FDG PET/CT: timing for evaluation of response to therapy remains a clinical challenge. American Journal of Nuclear Medicine and Molecular Imaging, 1(1), 63–64. -
-
Safety of repeated yttrium-90 radioembolization.
Lam, M. G. E. H., Louie, J. D., Iagaru, A. H., Goris, M. L., & Sze, D. Y. (2013). Safety of repeated yttrium-90 radioembolization. Cardiovascular and Interventional Radiology, 36(5), 1320–1328. -
Root cause analysis of gastroduodenal ulceration after yttrium-90 radioembolization.
Lam, M. G. E. H., Banerjee, S., Louie, J. D., Abdelmaksoud, M. H. K., Iagaru, A. H., Ennen, R. E., & Sze, D. Y. (2013). Root cause analysis of gastroduodenal ulceration after yttrium-90 radioembolization. Cardiovascular and Interventional Radiology, 36(6), 1536–1547. -
Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
Iagaru, A., Young, P., Mittra, E., Dick, D. W., Herfkens, R., & Gambhir, S. S. (2013). Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases. Clinical Nuclear Medicine, 38(7), e290–6. -
18F-FDG PET/CT Demonstration of Diffuse Lymphohistiocytic Granulomatous Vasculitis.
Kumar, M., & Iagaru, A. (2013). 18F-FDG PET/CT Demonstration of Diffuse Lymphohistiocytic Granulomatous Vasculitis. Clinical Nuclear Medicine. -
Second Sino-American Conference on Nuclear Medicine
Delbeke, D., Alessio, A., & Iagaru, A. (2013). Second Sino-American Conference on Nuclear Medicine. JOURNAL OF NUCLEAR MEDICINE, 54(4), 15N–16N. -
Tumor Metabolic Phenotypes on F-18 FDG PET REPLY
Iagaru, A. H., Gambhir, S. S., & Goris, M. L. (2009). Tumor Metabolic Phenotypes on F-18 FDG PET REPLY. JOURNAL OF NUCLEAR MEDICINE, 50(6), 1011–1012. -
Combined F-18-FDG and Fluoride Approach in PET/CT Imaging: Is There a Clinical Future? REPLY
Iagaru, A., Mittra, E., Goris, M. L., & Gambhir, S. S. (2010). Combined F-18-FDG and Fluoride Approach in PET/CT Imaging: Is There a Clinical Future? REPLY. JOURNAL OF NUCLEAR MEDICINE, 51(1), 166–167. -
Tumor Measurements by F-18-FDG PET: How Accurate are they?
Mittra, E., Iagaru, A., & Gambhir, S. S. (2010). Tumor Measurements by F-18-FDG PET: How Accurate are they? Presented at the 23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), VIENNA,AUSTRIA: SPRINGER. -
Combined F-18 Fluoride and F-18 FDG PET/CT Scan for Evaluation of Malignancy: Beyond the Pilot Phase Study
Iagaru, A., Mittra, E., Dick, D. W., & Gambhir, S. S. (2010). Combined F-18 Fluoride and F-18 FDG PET/CT Scan for Evaluation of Malignancy: Beyond the Pilot Phase Study. Presented at the 23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), VIENNA,AUSTRIA: SPRINGER. -
[F-18]FPPRGD2 PET/CT Imaging of Integrin Expression in Healthy Volunteers
Mittra, E., Iagaru, A., Goris, M. L., Chin, F., Chen, X., & Gambhir, S. S. (2010). [F-18]FPPRGD2 PET/CT Imaging of Integrin Expression in Healthy Volunteers. Presented at the 23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), VIENNA,AUSTRIA,AUSTRIA: SPRINGER. -
The Impact of Partial Volume Correction in the Evaluation of Solitary Pulmonary Nodules by FDG PET/CT in a Population at Intermediate Risk of Lung Cancer
Keu, K., Nair, V. S., Mittra, E., Gambhir, S. S., & Iagaru, A. (2012). The Impact of Partial Volume Correction in the Evaluation of Solitary Pulmonary Nodules by FDG PET/CT in a Population at Intermediate Risk of Lung Cancer. Presented at the 4th International Symposium on Targeted Radiotherapy and Dosimetry (ISTARD) in Conjunction with the 25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), MILAN,ITALY: SPRINGER. -
alpha v beta 3 Integrins as a Biomarker of Disease Recurrence in Glioblastoma Multiforme: Initial Clinical Results Using 18F FPPRGD2 PET/CT
Iagaru, A., Mosci, C., Mittra, E. S., Shin, B., Chin, F., & Gambhir, S. S. (2012). alpha v beta 3 Integrins as a Biomarker of Disease Recurrence in Glioblastoma Multiforme: Initial Clinical Results Using 18F FPPRGD2 PET/CT. Presented at the 4th International Symposium on Targeted Radiotherapy and Dosimetry (ISTARD) in Conjunction with the 25th Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), MILAN,ITALY: SPRINGER. -
Prospective Evaluation of Tc-99m-MDP Scintigraphy, F-18 NaF PET/CT and F-18 FDG PET/CT for Detection of Skeletal Metastases
Iagaru, A., Mittra, E., Dick, D., & Gambhir, S. S. (2009). Prospective Evaluation of Tc-99m-MDP Scintigraphy, F-18 NaF PET/CT and F-18 FDG PET/CT for Detection of Skeletal Metastases. SPRINGER. -
Efficacy of F-18-FDG PET/CT for Breast Cancer
Mittra, E., Quon, A., Gambhir, S. S., & Iagaru, A. (2009). Efficacy of F-18-FDG PET/CT for Breast Cancer. SPRINGER. -
Antithyroid drugs and radioiodine and the absence of evidence - Reply
McDougall, I. R., & Iagaru, A. (2007). Antithyroid drugs and radioiodine and the absence of evidence - Reply. JOURNAL OF NUCLEAR MEDICINE, 48(8), 1403–1404. -
Role or FDG-PET/CT Surveillance for Patients with Classical Hodgkin's Disease in First Complete Response: The Stanford University Experience.
Maeda, L. S., Horning, S. J., Iagaru, A. H., Lin, F. I., Hoppe, R. T., Rosenberg, S. A., & Advani, R. H. (2009). Role or FDG-PET/CT Surveillance for Patients with Classical Hodgkin's Disease in First Complete Response: The Stanford University Experience. BLOOD, 114(22), 626–26. -
Osseous and soft tissue sarcomas: When can F-18 FDG PET/CT evaluation provide useful information?
Iagaru, A., Quon, A., Jacobs, C., Marina, N., McDougall, I., & Gambhir, S. S. (2007). Osseous and soft tissue sarcomas: When can F-18 FDG PET/CT evaluation provide useful information? Presented at the 20th Annual Congress of the European-Association-of-Nuclear-Medicine, COPENHAGEN,DENMARK,DENMARK,DENMARK,DENMARK: SPRINGER. -
An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer.
Nair, V. S., Keu, K. V., Luttgen, M. S., Kolatkar, A., Vasanawala, M., Kuschner, W., … Kuhn, P. (2013). An observational study of circulating tumor cells and (18)F-FDG PET uptake in patients with treatment-naive non-small cell lung cancer. PloS One, 8(7). -
Imaging Tumor Angiogenesis: The Road to Clinical Utility
Iagaru, A., & Gambhir, S. S. (2013). Imaging Tumor Angiogenesis: The Road to Clinical Utility. AMERICAN JOURNAL OF ROENTGENOLOGY, 201(2), W183–W191. -
Imaging characteristics and response after intraarterial administration of the oncolytic herpes virus NV1020 to treat hepatic colorectal metastases
Sze, D. Y., Gambhir, S. S., Chari, R. S., Geller, D. A., Iagaru, A., Mescheder, A., … Tanabe, K. (2008). Imaging characteristics and response after intraarterial administration of the oncolytic herpes virus NV1020 to treat hepatic colorectal metastases. JOURNAL OF CLINICAL ONCOLOGY, 26(15). -
Phase II Efficacy Results Using an Oncolytic Herpes Simplex Virus (NV1020) in Patients with Colorectal Cancer Metastatic to Liver (mCRC)
Nemunaitis, J., Geevarghese, S. K., Geller, D. A., de Haan, H. A., Iagaru, A., Knoll, A., … Tanabe, K. (2009). Phase II Efficacy Results Using an Oncolytic Herpes Simplex Virus (NV1020) in Patients with Colorectal Cancer Metastatic to Liver (mCRC). Presented at the 12th Annual Meeting of the American Society of Gene Therapy, SAN DIEGO,CA: NATURE PUBLISHING GROUP. -
Phase II efficacy results using an oncolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC)
Geevarghese, S. K., Chen, A., Geller, D. A., de Haan, H. A., Iagaru, A., Knoll, A., … Tanabe, K. (2009). Phase II efficacy results using an oncolytic herpes simplex virus (NV1020) in patients with colorectal cancer metastatic to liver (mCRC). JOURNAL OF CLINICAL ONCOLOGY, 27(15). -
18F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder.
Takehana, C. S., Twist, C. J., Mosci, C., Quon, A., Mittra, E., & Iagaru, A. (2014). 18F-FDG PET/CT in the management of patients with post-transplant lymphoproliferative disorder. Nuclear Medicine Communications, 35(3), 276–281. -
The Clinical Use of PET/CT in the Evaluation of Melanoma.
Keu, K. V., & Iagaru, A. H. (2014). The Clinical Use of PET/CT in the Evaluation of Melanoma. Methods in Molecular Biology (Clifton, N.J.), 1102, 553–580. -
Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT.
Lam, M. G. E. H., Goris, M. L., Iagaru, A. H., Mittra, E. S., Louie, J. D., & Sze, D. Y. (2013). Prognostic utility of 90Y radioembolization dosimetry based on fusion 99mTc-macroaggregated albumin-99mTc-sulfur colloid SPECT. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 54(12), 2055–2061. -
Combined 18F-fluoride and 18F-FDG PET/CT: a response based on actual data from prospective studies.
Iagaru, A., Mosci, C., Dick, D. W., Sathekge, M., Lapa, P., de Lima, J. M., & Gambhir, S. S. (2013). Combined 18F-fluoride and 18F-FDG PET/CT: a response based on actual data from prospective studies. European Journal of Nuclear Medicine and Molecular Imaging, 40(12), 1922–1924. -
-
(18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients.
Iagaru, A., Mosci, C., Shen, B., Chin, F. T., Mittra, E., Telli, M. L., & Gambhir, S. S. (2014). (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients. Radiology, 273(2), 549–59. -
-
Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases.
Iagaru, A., Young, P., Mittra, E., Dick, D. W., Herfkens, R., & Gambhir, S. S. (2013). Pilot prospective evaluation of 99mTc-MDP scintigraphy, 18F NaF PET/CT, 18F FDG PET/CT and whole-body MRI for detection of skeletal metastases. Clinical Nuclear Medicine, 38(7), e290–6. -
Circulating Tumor Microemboli Diagnostics for Patients with Non-Small-Cell Lung Cancer
Carlsson, A., Nair, V. S., Luttgen, M. S., Keu, K. V., Horng, G., Vasanawala, M., … Gambhir, S. S. (2014). Circulating Tumor Microemboli Diagnostics for Patients with Non-Small-Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 9(8), 1111–1119. -
-
Simultaneous Whole-Body Time-of-Flight F-18-FDG PET/MRI A Pilot Study Comparing SUVmax With PET/CT and Assessment of MR Image Quality
Iagaru, A., Mittra, E., Minamimoto, R., Jamali, M., Levin, C., Quon, A., … Zaharchuk, G. (2015). Simultaneous Whole-Body Time-of-Flight F-18-FDG PET/MRI A Pilot Study Comparing SUVmax With PET/CT and Assessment of MR Image Quality. CLINICAL NUCLEAR MEDICINE, 14(1), 1–8. -
Simultaneous whole-body time-of-flight 18F-FDG PET/MRI: a pilot study comparing SUVmax with PET/CT and assessment of MR image quality.
Iagaru, A., Mittra, E., Minamimoto, R., Jamali, M., Levin, C., Quon, A., … Zaharchuk, G. (2015). Simultaneous whole-body time-of-flight 18F-FDG PET/MRI: a pilot study comparing SUVmax with PET/CT and assessment of MR image quality. Clinical Nuclear Medicine, 40(1), 1–8. -
Thyroid carcinoma, version 2.2014.
Tuttle, R. M., Haddad, R. I., Ball, D. W., Byrd, D., Dickson, P., Duh, Q.-Y., … Hughes, M. (2014). Thyroid carcinoma, version 2.2014. Journal of the National Comprehensive Cancer Network , 12(12), 1671–80. -
Radioembolization Dosimetry: The Road Ahead
Smits, M. L. J., Elschot, M., Sze, D. Y., Kao, Y. H., Nijsen, J. F. W., Iagaru, A. H., … Lam, M. G. E. H. (2015). Radioembolization Dosimetry: The Road Ahead. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 38(2), 261–269. -
Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone.
Sampath, S. C., Sampath, S. C., Mosci, C., Lutz, A. M., Willmann, J. K., Mittra, E. S., … Iagaru, A. (2015). Detection of osseous metastasis by 18F-NaF/18F-FDG PET/CT versus CT alone. Clinical Nuclear Medicine, 40(3), e173–7. -
Validation of 64Cu-DOTA-rituximab injection preparation under good manufacturing practices: a PET tracer for imaging of B-cell non-Hodgkin lymphoma.
Natarajan, A., Arksey, N., Iagaru, A., Chin, F. T., & Gambhir, S. S. (2015). Validation of 64Cu-DOTA-rituximab injection preparation under good manufacturing practices: a PET tracer for imaging of B-cell non-Hodgkin lymphoma. Molecular Imaging, 14. -
18F-sodium fluoride PET/CT in oncology: an atlas of SUVs.
Sabbah, N., Jackson, T., Mosci, C., Jamali, M., Minamimoto, R., Quon, A., … Iagaru, A. (2015). 18F-sodium fluoride PET/CT in oncology: an atlas of SUVs. Clinical Nuclear Medicine, 40(4), e228–31. -
-
Glioblastoma Multiforme Recurrence: An Exploratory Study of F-18 FPPRGD(2) PET/CT1
Iagaru, A., Mosci, C., Mittra, E., Zaharchuk, G., Fischbein, N., Harsh, G., … Gambhir, S. S. (2015). Glioblastoma Multiforme Recurrence: An Exploratory Study of F-18 FPPRGD(2) PET/CT1. RADIOLOGY, 277(2), 497–506. -
-
-
Stereotactic ablative radiotherapy for the treatment of refractory cardiac ventricular arrhythmia.
Loo, B. W., Soltys, S. G., Wang, L., Lo, A., Fahimian, B. P., Iagaru, A., … Zei, P. (2015). Stereotactic ablative radiotherapy for the treatment of refractory cardiac ventricular arrhythmia. Circulation. Arrhythmia and Electrophysiology, 8(3), 748–50. -
Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types
Lam, M. G. E. H., Banerjee, A., Goris, M. L., Iagaru, A. H., Mittra, E. S., Louie, J. D., & Sze, D. Y. (2015). Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 42(8), 1192–1201. -
Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
Minamimoto, R., Loening, A., Jamali, M., Barkhodari, A., Mosci, C., Jackson, T., … Iagaru, A. (2015). Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. Journal of Nuclear Medicine , 56(12), 1862–68. -
-
-
123I accumulation in thoracic neoesophagus masking residual papillary thyroid cancer.
Jackson, T., Sabbah, N., & Iagaru, A. (2015). 123I accumulation in thoracic neoesophagus masking residual papillary thyroid cancer. Clinical Nuclear Medicine, 40(2), e150–1. -
Successful treatment of systemic and central nervous system post-transplant lymphoproliferative disorder without the use of high-dose methotrexate or radiation.
Mahapatra, S., Chin, C. C., Iagaru, A., Heerema-McKenney, A., & Twist, C. J. (2014). Successful treatment of systemic and central nervous system post-transplant lymphoproliferative disorder without the use of high-dose methotrexate or radiation. Pediatric Blood & Cancer, 61(11), 2107–2109. -
Validation of 64Cu-DOTA-rituximab injection preparation under good manufacturing practices: a PET tracer for imaging of B-cell non-Hodgkin lymphoma.
Natarajan, A., Arksey, N., Iagaru, A., Chin, F. T., & Gambhir, S. S. (2015). Validation of 64Cu-DOTA-rituximab injection preparation under good manufacturing practices: a PET tracer for imaging of B-cell non-Hodgkin lymphoma. Molecular Imaging, 14. -
-
-
-
Pilot Comparison of Ga-68-RM2 PET and Ga-68-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer
Minamimoto, R., Hancock, S., Schneider, B., Chin, F. T., Jamali, M., Loening, A., … Iagaru, A. (2016). Pilot Comparison of Ga-68-RM2 PET and Ga-68-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE, 57(4), 557–62. -
-
-
-
Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.
Iagaru, A., Mosci, C., Mittra, E., Zaharchuk, G., Fischbein, N., Harsh, G., … Gambhir, S. S. (2016). Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT. Radiology, 280(1), 328-? -
Clinical significance of extraskeletal computed tomography findings on 18F-NaF PET/CT performed for osseous metastatic disease evaluation.
Guo, H. H., Moradi, F., & Iagaru, A. (2016). Clinical significance of extraskeletal computed tomography findings on 18F-NaF PET/CT performed for osseous metastatic disease evaluation. Nuclear Medicine Communications, 37(9), 975–82. -
Pilot prospective evaluation of F-18-FPPRGD(2) PET/CT in patients with cervical and ovarian cancer
Minamimoto, R., Karam, A., Jamali, M., Barkhodari, A., Gambhir, S. S., Dorigo, O., & Iagaru, A. (2016). Pilot prospective evaluation of F-18-FPPRGD(2) PET/CT in patients with cervical and ovarian cancer. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 43(6), 1047–55. -
PET Imaging of Skull Base Neoplasms.
Mittra, E. S., Iagaru, A., Quon, A., & Fischbein, N. (2007). PET Imaging of Skull Base Neoplasms. PET Clinics, 2(4), 489–510. -
-
Spectrum of Ga-68-DOTA TATE Uptake in Patients With Neuroendocrine Tumors
Moradi, F., Jamali, M., Barkhodari, A., Schneider, B., Chin, F., Quon, A., … Iagaru, A. (2016). Spectrum of Ga-68-DOTA TATE Uptake in Patients With Neuroendocrine Tumors. CLINICAL NUCLEAR MEDICINE, 41(6), E281–E287. -
(18)F NaF PET/CT in the Assessment of Malignant Bone Disease.
Mosci, C., & Iagaru, A. (2012). (18)F NaF PET/CT in the Assessment of Malignant Bone Disease. PET Clinics, 7(3), 263–274. -
-
(18)F-FDG-PET and PET/CT for Evaluating Primary Bone Tumors.
Mittra, E., & Iagaru, A. (2010). (18)F-FDG-PET and PET/CT for Evaluating Primary Bone Tumors. PET Clinics, 5(3), 327–339. -
Improvements in PET Image Quality in Time of Flight (TOF) Simultaneous PET/MRI.
Minamimoto, R., Levin, C., Jamali, M., Holley, D., Barkhodari, A., Zaharchuk, G., & Iagaru, A. (2016). Improvements in PET Image Quality in Time of Flight (TOF) Simultaneous PET/MRI. Molecular Imaging and Biology , 18(5), 776–81. -
PET Imaging Toward Individualized Management of Urologic and Gynecologic Malignancies.
Sonni, I., & Iagaru, A. (2016). PET Imaging Toward Individualized Management of Urologic and Gynecologic Malignancies. PET Clinics, 11(3), 261–72. -
-
-
-
-
-
Assessment of skeletal tumour burden on 18F-NaF PET/CT using a new quantitative method.
Lapa, P., Marques, M., Costa, G., Iagaru, A., & Pedroso de Lima, J. (2017). Assessment of skeletal tumour burden on 18F-NaF PET/CT using a new quantitative method. Nuclear Medicine Communications. -
Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin.
Sonni, I., Baratto, L., & Iagaru, A. (2017). Imaging of Prostate Cancer Using Gallium-68-Labeled Bombesin. PET Clinics, 12(2), 159–71. -
18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT.
Baratto, L., Park, S. Y., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S. S., & Iagaru, A. (2017). 18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT. PloS One, 12(6). -
Initial Experience With Simultaneous 18F-FDG PET/MRI in the Evaluation of Cardiac Sarcoidosis and Myocarditis.
Hanneman, K., Kadoch, M., Guo, H. H., Jamali, M., Quon, A., Iagaru, A., & Herfkens, R. (2017). Initial Experience With Simultaneous 18F-FDG PET/MRI in the Evaluation of Cardiac Sarcoidosis and Myocarditis. Clinical Nuclear Medicine, 42(7), e328–e334. -
-
Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET/MR: a dual centre experience.
Ter Voert, E. E. G. W., Veit-Haibach, P., Ahn, S., Wiesinger, F., Khalighi, M. M., Levin, C. S., … Delso, G. (2017). Clinical evaluation of TOF versus non-TOF on PET artifacts in simultaneous PET/MR: a dual centre experience. European Journal of Nuclear Medicine and Molecular Imaging, 44(7), 1223–33. -
American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Body.
Subramaniam, R. M., Jadvar, H., Colletti, P. M., Guimaraes, A., Gullapali, R., Iagaru, A. H., … Oates, M. E. (2017). American College of Radiology and Society of Nuclear Medicine and Molecular Imaging Joint Credentialing Statement for PET/MR Imaging: Body. Journal of Nuclear Medicine . -
Dynamic brain PET/MR using TOF reconstruction.
Khalighi, M. M., Delso, G., Tohme, M., Iagaru, A., & Zaharchuk, G. (2015). Dynamic brain PET/MR using TOF reconstruction. EJNMMI Physics, 2, A60-? -
Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Conventional Imaging.
Minamimoto, R., Sonni, I., Hancock, S., Vasanawala, S., Loening, A., Gambhir, S. S., & Iagaru, A. (2017). Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Conventional Imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Anaplastic Thyroid Cancer With Extensive Skeletal Muscle Metastases on 18F-FDG PET/CT.
Yurkiewicz, I. R., Ganjoo, K. N., & Iagaru, A. (2018). Anaplastic Thyroid Cancer With Extensive Skeletal Muscle Metastases on 18F-FDG PET/CT. Clinical Nuclear Medicine. -
-
-
SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions
Baratto, L., Park, S., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S., & Iagaru, A. (2017). SiPM PET/CT vs. Standard PET/CT: A Pilot Study Comparing Semi-Quantitative Measurements in Normal Tissues and Lesions. JOURNAL OF NUCLEAR MEDICINE, 58. -
-
-
Biodistribution and kinetics of 18F FPPRGD2 in cancer patients
Davidzon, G., Mosci, C., Mittra, E., Shen, B., Chin, F., Gambhir, S., & Iagaru, A. (2013). Biodistribution and kinetics of 18F FPPRGD2 in cancer patients. JOURNAL OF NUCLEAR MEDICINE, 54. -
-
-
-
-
First evaluation of a time-of-flight whole-body PET/MRI scanner in oncology patients: comparison with PET/CT
Iagaru, A., Jamali, M., Minamimoto, R., Mittra, E., Gold, G., Vasanwala, S., … Zaharchuk, G. (2014). First evaluation of a time-of-flight whole-body PET/MRI scanner in oncology patients: comparison with PET/CT. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
Developing a non-invasive, diagnostic test for stage I non-small cell lung cancer using circulating tumor cells.
Luttgen, M. S., Keu, K. V., Nair, V. S., Horng, G., Vasanawala, M., Kolatkar, A., … Gambhir, S. S. (2013). Developing a non-invasive, diagnostic test for stage I non-small cell lung cancer using circulating tumor cells. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
-
F-18 FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas: Differences between Adult and Pediatric Patients
Iagaru, A., Mittra, E., Quon, A., Jacobs, C., Marina, N., & Gambhir, S. S. (2008). F-18 FDG PET/CT Evaluation of Osseous and Soft Tissue Sarcomas: Differences between Adult and Pediatric Patients. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
Ga-68-DOTA-Bombesin (Ga-68-RM2 or Ga-68-Bombesin) PET versus Ga-68-PSMA PET: A pilot prospective evaluation in patients with biochemical recurrence of prostate cancer.
Iagaru, A., Minamimoto, R., Hancock, S. L., Mittra, E., Loening, A., & Vasanawala, S. (2016). Ga-68-DOTA-Bombesin (Ga-68-RM2 or Ga-68-Bombesin) PET versus Ga-68-PSMA PET: A pilot prospective evaluation in patients with biochemical recurrence of prostate cancer. JOURNAL OF CLINICAL ONCOLOGY, 34(2). -
Combined NaF/FDG PET/CT evaluation of prostate cancer patients
Iagaru, A., Mosci, C., Keu, K. V., Mittra, E., Hancock, S., Pachynski, R., … Gambhir, S. (2014). Combined NaF/FDG PET/CT evaluation of prostate cancer patients. JOURNAL OF NUCLEAR MEDICINE, 55. -
Does The White Blood Cell Count Assist With Solitary Pulmonary Nodule Diagnosis?
Nair, V. S., Rosenberg, J., Horng, G., Jamali, M., Tripathi, P., Iagaru, A., … Gambhir, S. S. (2015). Does The White Blood Cell Count Assist With Solitary Pulmonary Nodule Diagnosis? AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE. AMER THORACIC SOC. -
Correlating circulating tumor cells with F-18-FDG positron emission tomography (PET) uptake in patients with treatment naive non-small cell lung cancer: A pilot study
Kuhn, P., Keu, K. V., Nair, V. S., Luttgen, M., Maestas, S., Bethel, K., … Gambhir, S. S. (2012). Correlating circulating tumor cells with F-18-FDG positron emission tomography (PET) uptake in patients with treatment naive non-small cell lung cancer: A pilot study. CANCER RESEARCH. AMER ASSOC CANCER RESEARCH. -
Relative value of three whole-body MR approaches for PET-MR, including gadofosveset-enhanced MR, in comparison to PET-CT.
Obara, P., Loening, A., Taviani, V., Iagaru, A., Hargreaves, B. A., & Vasanawala, S. (2017). Relative value of three whole-body MR approaches for PET-MR, including gadofosveset-enhanced MR, in comparison to PET-CT. Clinical Imaging, 48, 62–68. -
Quantitative imaging of bone-cartilage interactions in ACL-injured patients with PET-MRI.
Kogan, F., Fan, A. P., Monu, U., Iagaru, A., Hargreaves, B. A., & Gold, G. E. (2018). Quantitative imaging of bone-cartilage interactions in ACL-injured patients with PET-MRI. Osteoarthritis and Cartilage. -
Initial experience with a SiPM-based PET/CT scanner: influence of acquisition time on image quality
Sonni, I., Baratto, L., Park, S., Hatami, N., Srinivas, S., Davidzon, G., … Iagaru, A. (2018). Initial experience with a SiPM-based PET/CT scanner: influence of acquisition time on image quality. EJNMMI PHYSICS, 5, 9. -
F-18 NaF Brain Metastasis Uptake in a Patient with Melanoma
Jones, R. P., & Iagaru, A. (2014). F-18 NaF Brain Metastasis Uptake in a Patient with Melanoma. CLINICAL NUCLEAR MEDICINE, 39(10), E448–E450. -
Intragastric Meal Distribution During Gastric Emptying Scintigraphy for Assessment of Fundic Accommodation: Correlation with Symptoms of Gastroparesis
Orthey, P., Yu, D., Van Natta, M. L., Ramsey, F. V., Diaz, J. R., Bennett, P. A., … Maurer, A. H. (2018). Intragastric Meal Distribution During Gastric Emptying Scintigraphy for Assessment of Fundic Accommodation: Correlation with Symptoms of Gastroparesis. JOURNAL OF NUCLEAR MEDICINE, 59(4), 691–97. -
Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer.
Park, S. Y., Zacharias, C., Harrison, C., Fan, R. E., Kunder, C., Hatami, N., … Iagaru, A. (2018). Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer. Radiology, 172232. -
-
-
-
-
-
-
-
-
Ga-68 PSMA 11 PET/MRI in Patients with Newly Diagnosed Intermediate and High-Risk Prostate Cancers
Zacharias, C., Harrison, C., Ghanouni, P., Sonn, G., & Iagaru, A. (2017). Ga-68 PSMA 11 PET/MRI in Patients with Newly Diagnosed Intermediate and High-Risk Prostate Cancers. JOURNAL OF NUCLEAR MEDICINE, 58. -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
18F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition.
Baratto, L., Park, S. Y., Hatami, N., Gulaka, P., Vasanawala, S., Yohannan, T. K., … Iagaru, A. (2018). 18F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition. EJNMMI Research, 8(1), 66. -
Combined 68Ga-NOTA-PRGD2 and 18F-FDG PET/CT Can Discriminate Uncommon Meningioma Mimicking High-Grade Glioma.
Li, D., Zhang, J., Ji, N., Zhao, X., Zheng, K., Qiao, Z., … Chen, X. (2018). Combined 68Ga-NOTA-PRGD2 and 18F-FDG PET/CT Can Discriminate Uncommon Meningioma Mimicking High-Grade Glioma. Clinical Nuclear Medicine. -
Clinical Evaluation of Ga-68-PSMA-Iota Iota and Ga-68-RM2 PET Images Reconstructed With an Improved Scatter Correction Algorithm
Wangerin, K. A., Baratto, L., Khalighi, M. M., Hope, T. A., Gulaka, P. K., Deller, T. W., & Iagaru, A. H. (2018). Clinical Evaluation of Ga-68-PSMA-Iota Iota and Ga-68-RM2 PET Images Reconstructed With an Improved Scatter Correction Algorithm. AMERICAN JOURNAL OF ROENTGENOLOGY, 211(3), 655–60. -
Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management
Song, H., Mosci, C., Akatsu, H., Basina, M., Dosiou, C., & Iagaru, A. (2018). Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management. CLINICAL NUCLEAR MEDICINE, 43(10), 705–9. -
-
-
-
-
-
-
-
-
-
Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients with Cardiac Sarcoidosis.
Ning, N., Guo, H. H., Iagaru, A., Mittra, E., Fowler, M., & Witteles, R. (2019). Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients with Cardiac Sarcoidosis. Journal of Cardiac Failure. -
-
Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT.
Iagaru, A., Mosci, C., Mittra, E., Zaharchuk, G., Fischbein, N., Harsh, G., … Gambhir, S. S. (2015). Glioblastoma Multiforme Recurrence: An Exploratory Study of (18)F FPPRGD2 PET/CT. Radiology, 141550. -
Nuclear Medicine Imaging Techniques for Detection of Skeletal Metastases in Breast Cancer.
Iagaru, A., & Minamimoto, R. (2018). Nuclear Medicine Imaging Techniques for Detection of Skeletal Metastases in Breast Cancer. PET Clinics, 13(3), 383–393. -
Editorial Comment.
Iagaru, A. (2016). Editorial Comment. The Journal of Urology, 196(2), 390. -
Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients With Cardiac Sarcoidosis
Ning, N., Guo, H. H., Iagaru, A., Mittra, E., Fowler, M., & Witteles, R. (2019). Serial Cardiac FDG-PET for the Diagnosis and Therapeutic Guidance of Patients With Cardiac Sarcoidosis. JOURNAL OF CARDIAC FAILURE, 25(4), 307–11. -
Improved Scatter Correction to Eliminate Halo-Artifacts for 68Ga-labeled Radiopharmaceuticals in PET Imaging.
Wangerin, K. A., & Iagaru, A. (2019). Improved Scatter Correction to Eliminate Halo-Artifacts for 68Ga-labeled Radiopharmaceuticals in PET Imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
-
-
68Ga Scatter Correction to Eliminate Halo-Artifacts in PET Imaging.
Wangerin, K., & Iagaru, A. (2019). 68Ga Scatter Correction to Eliminate Halo-Artifacts in PET Imaging. Urology. -
Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[18F] F and [18F]FDG: a Focus on Skeletal Lesions.
Sonni, I., Minamimoto, R., Baratto, L., Gambhir, S. S., Loening, A. M., Vasanawala, S. S., & Iagaru, A. (2019). Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[18F] F and [18F]FDG: a Focus on Skeletal Lesions. Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging. -
-
-
-
Prospective Evaluation of F-18-DCFPyL PET/CT and Conventional Imaging in Patients with Biochemically Recurrent Prostate Cancer
Song, H., Harrison, C., Guja, K., Franc, B., Moradi, F., Davidzon, G., … Iagaru, A. (2019). Prospective Evaluation of F-18-DCFPyL PET/CT and Conventional Imaging in Patients with Biochemically Recurrent Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
-
Prospective evaluation of Ga-68-RM2 PET/MRI and Ga-68-PSMA11 PET/CT in patients with biochemical recurrence of prostate cancer
Baratto, L., Duan, H., Hatami, N., Toriihara, A., Song, H., & Iagaru, A. (2019). Prospective evaluation of Ga-68-RM2 PET/MRI and Ga-68-PSMA11 PET/CT in patients with biochemical recurrence of prostate cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
-
Prospective Comparison of F-18-DCFPyL PET/CT with F-18-NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer
Duan, H., Song, H., Baratto, L., Khalaf, M., Hatami, N., Franc, B., … Iagaru, A. (2019). Prospective Comparison of F-18-DCFPyL PET/CT with F-18-NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Prospective evaluation of F-18- DCFPyL in Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels
Harrison, C., Song, H., Franc, B. L., Guja, K., Moradi, F., Davidzon, G., … Iagaru, A. (2019). Prospective evaluation of F-18- DCFPyL in Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
-
Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors.
Toriihara, A., Baratto, L., Nobashi, T., Park, S., Hatami, N., Davidzon, G., … Iagaru, A. (2019). Prognostic value of somatostatin receptor expressing tumor volume calculated from 68Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging. -
18F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma.
Laudicella, R., Davidzon, G., Vasanawala, S., Baldari, S., & Iagaru, A. (2019). 18F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma. Nuclear Medicine and Molecular Imaging, 53(4), 296–299. -
-
Multimodality Hyperpolarized C-13 MRS/PET/Multiparametric MR Imaging for Detection and Image-Guided Biopsy of Prostate Cancer: First Experience in a Canine Prostate Cancer Model
Bachawal, S. V., Park, J. M., Valluru, K. S., Loft, M. D., Felt, S. A., Vilches-Moure, J. G., … Willmann, J. K. (2019). Multimodality Hyperpolarized C-13 MRS/PET/Multiparametric MR Imaging for Detection and Image-Guided Biopsy of Prostate Cancer: First Experience in a Canine Prostate Cancer Model. MOLECULAR IMAGING AND BIOLOGY, 21(5), 861–70. -
-
Comparison of three interpretation criteria of 68Ga-PSMA11 PET based on inter- and intra-reader agreement.
Toriihara, A., Nobashi, T., Baratto, L., Duan, H., Moradi, F., Park, S., … Iagaru, A. (2019). Comparison of three interpretation criteria of 68Ga-PSMA11 PET based on inter- and intra-reader agreement. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Initial experience with a PET/computed tomography system using silicon photomultiplier detectors.
Park, S. Y., Barrato, L., Hatami, N., Davidzon, G., Gambhir, S. S., & Iagaru, A. (2019). Initial experience with a PET/computed tomography system using silicon photomultiplier detectors. Nuclear Medicine Communications. -
Optimization of 89Zr PET imaging for improved multi-site quantification and lesion detection using an anthropomorphic phantom.
Christian, P. E., Williams, S. P., Burrell, L. D., Castaneda, P., Albani, J., Sandella, N., … Sanabria Bohorquez, S. M. (2019). Optimization of 89Zr PET imaging for improved multi-site quantification and lesion detection using an anthropomorphic phantom. Journal of Nuclear Medicine Technology. -
Evaluation of integrin alphavbeta6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis.
Kimura, R. H., Wang, L., Shen, B., Huo, L., Tummers, W., Filipp, F. V., … Gambhir, S. S. (2019). Evaluation of integrin alphavbeta6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis. Nature Communications, 10(1), 4673. -
Prospective Evaluation in an Academic Center of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management.
Song, H., Harrison, C., Duan, H., Guja, K., Hatami, N., Franc, B., … Iagaru, A. (2019). Prospective Evaluation in an Academic Center of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Performance Comparison of Individual and Ensemble CNN Models for the Classification of Brain 18F-FDG-PET Scans.
Nobashi, T., Zacharias, C., Ellis, J. K., Ferri, V., Koran, M. E., Franc, B. L., … Davidzon, G. A. (2019). Performance Comparison of Individual and Ensemble CNN Models for the Classification of Brain 18F-FDG-PET Scans. Journal of Digital Imaging. -
-
-
-
-
-
-
Malignant cutaneous melanoma:updates inPET imaging.
Laudicella, R., Baratto, L., Minutoli, F., Baldari, S., & Iagaru, A. (2019). Malignant cutaneous melanoma:updates inPET imaging. Current Radiopharmaceuticals. -
-
The Role of PET/CT in the Imaging of Pancreatic Neoplasms.
Duan, H., Baratto, L., & Iagaru, A. (2019). The Role of PET/CT in the Imaging of Pancreatic Neoplasms. Seminars in Ultrasound, CT, and MR, 40(6), 500–508. -
Human biodistribution and radiation dosimetry of [18F]DASA-23, a PET probe targeting pyruvate kinase M2.
Beinat, C., Patel, C. B., Haywood, T., Shen, B., Naya, L., Gandhi, H., … Gambhir, S. S. (2020). Human biodistribution and radiation dosimetry of [18F]DASA-23, a PET probe targeting pyruvate kinase M2. European Journal of Nuclear Medicine and Molecular Imaging. -
Response to: Letter to the Editors: Re: Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[18F]F and [18F]FDG: A Focus on Skeletal Lesions.
Sonni, I., Minamimoto, R., Baratto, L., & Iagaru, A. (2020). Response to: Letter to the Editors: Re: Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[18F]F and [18F]FDG: A Focus on Skeletal Lesions. Molecular Imaging and Biology. -
Shifting Trends and Informed Decision Making in the Management of Graves' Disease.
Seib, C. D., Chen, J., & Iagaru, A. (2020). Shifting Trends and Informed Decision Making in the Management of Graves' Disease. Thyroid : Official Journal of the American Thyroid Association. -
Imaging the Distribution of Gastrin Releasing Peptide Receptors in Cancer.
Baratto, L., Duan, H., Maecke, H. R., & Iagaru, A. (2020). Imaging the Distribution of Gastrin Releasing Peptide Receptors in Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.
Nakamoto, R., Zaba, L. C., Rosenberg, J., Reddy, S. A., Nobashi, T. W., Davidzon, G., … Franc, B. L. (2020). Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging. -
ACR Stakeholder Prostate Summit.
Weinreb, J., Choyke, P., Iagaru, A., Ippolito, J., Lockhart, M., Merrick, G., … Rosenkrantz, A. (2020). ACR Stakeholder Prostate Summit. Journal of the American College of Radiology : JACR. -
The Effect of Various ß Values on Image Quality and Semiquantitative Measurements in 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI Images Reconstructed With a Block Sequential Regularized Expectation Maximization Algorithm.
Baratto, L., Duan, H., Ferri, V., Khalighi, M., & Iagaru, A. (2020). The Effect of Various ß Values on Image Quality and Semiquantitative Measurements in 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI Images Reconstructed With a Block Sequential Regularized Expectation Maximization Algorithm. Clinical Nuclear Medicine. -
Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET)
Duan, H., Ninatti, G., Girod, B., Ferri, V., Kunz, P. L., Fisher, G. A., … Mari, C. (2020). Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET). JOURNAL OF CLINICAL ONCOLOGY, 38(4). -
Deep learning detection of prostate cancer recurrence with 18F-FACBC (fluciclovine, Axumin®) positron emission tomography.
Lee, J. J., Yang, H., Franc, B. L., Iagaru, A., & Davidzon, G. A. (2020). Deep learning detection of prostate cancer recurrence with 18F-FACBC (fluciclovine, Axumin®) positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging. -
PET/MR in neuro-oncology: is it ready for prime-time?
Laudicella, R., Iagaru, A., Minutoli, F., Gaeta, M., Baldari, S., & Bisdas, S. (2020). PET/MR in neuro-oncology: is it ready for prime-time? CLINICAL AND TRANSLATIONAL IMAGING. -
Pulmonary Adenocarcinoma Metastasis to the Breast Unexpectedly Discovered on Re-staging 18F-FDG PET/CT in a Woman With a Normal Screening Mammogram.
Kozlov, A., Pantel, A., Iagaru, A., & Ikeda, D. (2020). Pulmonary Adenocarcinoma Metastasis to the Breast Unexpectedly Discovered on Re-staging 18F-FDG PET/CT in a Woman With a Normal Screening Mammogram. Clinical Lung Cancer. -
Clinical application of Fluciclovine PET, choline PET and gastrin-releasing polypeptide receptor (bombesin) targeting PET in prostate cancer.
Ceci, F., Castellucci, P., Polverari, G., & Iagaru, A. (2020). Clinical application of Fluciclovine PET, choline PET and gastrin-releasing polypeptide receptor (bombesin) targeting PET in prostate cancer. Current Opinion in Urology. -
Will FAPI PET/CT Replace FDG PET/CT in the Next Decade?-Counterpoint: No, not so fast!
Moradi, F., & Iagaru, A. (2020). Will FAPI PET/CT Replace FDG PET/CT in the Next Decade?-Counterpoint: No, not so fast! AJR. American Journal of Roentgenology. -
Sanjiv Sam Gambhir obituary for EJNMMI.
Iagaru, A., & McDougall, I. R. (2020). Sanjiv Sam Gambhir obituary for EJNMMI. European Journal of Nuclear Medicine and Molecular Imaging. -
The Role of Positron Emission Tomography in Pancreatic Cancer and Gallbladder Cancer.
Moradi, F., & Iagaru, A. (2020). The Role of Positron Emission Tomography in Pancreatic Cancer and Gallbladder Cancer. Seminars in Nuclear Medicine, 50(5), 434–46. -
Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy.
Nakamoto, R., C Zaba, L., Rosenberg, J., Arani Reddy, S., W Nobashi, T., Ferri, V., … Lewis Franc, B. (2020). Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy. Molecular Imaging and Biology. -
Sanjiv Sam Gambhir (November 23, 1962-July 18, 2020).
James, M., & Iagaru, A. (2020). Sanjiv Sam Gambhir (November 23, 1962-July 18, 2020). Molecular Imaging and Biology. -
INTERIM ANALYSIS RESULTS OF A PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING
Baratto, L., Song, H., Duan, H., Aparici, C. M., Hatami, N., Davidzon, G., … Iagaru, A. (2020). INTERIM ANALYSIS RESULTS OF A PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
In Memoriam: Sanjiv "Sam" Gambhir, MD, PhD 1962-2020.
Iagaru, A., & McDougall, I. R. (2020). In Memoriam: Sanjiv "Sam" Gambhir, MD, PhD 1962-2020. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 61(9), 20N–21N. -
An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on [18F]FDG PET/CT.
Guja, K. E., Brown, R., Girod, B., Song, H., Harrison, C., Franc, B. L., … Aparici, C. M. (2020). An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on [18F]FDG PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. -
Obituary for Sanjiv Sam Gambhir, MD, PhD.
Davidzon, G., Franc, B., Mari Aparici, C., Moradi, F., Nguyen, J., & Iagaru, A. (2020). Obituary for Sanjiv Sam Gambhir, MD, PhD. Clinical Nuclear Medicine. -
Sanjiv "Sam" Gambhir, MD, PhD 1962-2020 IN MEMORY
Iagaru, A., & McDougall, I. R. (2020). Sanjiv "Sam" Gambhir, MD, PhD 1962-2020 IN MEMORY. JOURNAL OF NUCLEAR MEDICINE, 61(9), 20N–21N. -
Visualization of diagnostic and therapeutic targets in glioma with molecular imaging
Li, D., Patel, C. B., Xu, G., Iagaru, A., Zhu, Z., Zhang, L., & Cheng, Z. (2020). Visualization of diagnostic and therapeutic targets in glioma with molecular imaging. Frontiers in Immunology. -
Prospective evaluation of F-18-DCFPyL PET/CT in biochemically recurrent prostate cancer: Analysis of lesion localization and distribution.
Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., Franc, B. L., … Iagaru, A. (2020). Prospective evaluation of F-18-DCFPyL PET/CT in biochemically recurrent prostate cancer: Analysis of lesion localization and distribution. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY. -
Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR).
Morris, M. J., Carroll, P. R., Saperstein, L., Pouliot, F., Josephson, D., Wong, J. Y. C., … Siegel, B. (2020). Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): Results from a phase III, prospective, multicenter study (CONDOR). JOURNAL OF CLINICAL ONCOLOGY, 38(15). -
A pilot study of F-18-FSPG SiPM-based PET/CT in patients referred for exclusion of active cardiac sarcoidosis and negative or non-diagnostic F-18-FDG PET/CT
Duan, H., Hatami, N., Baratto, L., Davidzon, G., Aparici, C. M., Gambhir, S., … Iagaru, A. (2020). A pilot study of F-18-FSPG SiPM-based PET/CT in patients referred for exclusion of active cardiac sarcoidosis and negative or non-diagnostic F-18-FDG PET/CT. JOURNAL OF NUCLEAR MEDICINE, 61. -
High Quality Isotropic Whole-body PET Imaging Using MR Priors
Khalighi, M. M., Deller, T., Spangler-Bickell, M., Wangerin, K., Holley, D., Halbert, K., … Moseley, M. (2020). High Quality Isotropic Whole-body PET Imaging Using MR Priors. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Prognostic values of quantitative and morphological parameters of dbPET in patients with luminal-type breast cancer: A pilot study
Miyake, K., Nakamoto, Y., Ikeda, D., Iagaru, A., Daniel, B., Lipson, J., … Togashi, K. (2020). Prognostic values of quantitative and morphological parameters of dbPET in patients with luminal-type breast cancer: A pilot study. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Extrahepatic Ga-68-DOTATATE-Avid Tumor Volume and serum Chromogranin A Predict Short-Term Outcome of Lu-177-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Song, H., Kunz, P., Franc, B., Moradi, F., Fisher, G., Aparici, C. M., … Davidzon, G. (2020). Extrahepatic Ga-68-DOTATATE-Avid Tumor Volume and serum Chromogranin A Predict Short-Term Outcome of Lu-177-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A two-year single institution experience
Duan, H., Ninatti, G., Girod, B., Ferri, V., Guja, K., Song, H., … Aparici, C. M. (2020). Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A two-year single institution experience. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs)
Duan, H., Girod, B., Ninatti, G., Ferri, V., Kunz, P., Fisher, G., … Aparici, C. M. (2020). Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs). JOURNAL OF NUCLEAR MEDICINE, 61. -
Key components of a successful PET/MR department
Holley, D., Khalighi, M. M., Iagaru, A., & Gold, G. (2020). Key components of a successful PET/MR department. JOURNAL OF NUCLEAR MEDICINE, 61. -
Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., … Franc, B. (2020). Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy
Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., … Franc, B. (2020). Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
PSMA-and GRPR-targeted PET: Preliminary Results in Patients with Biochemically Recurrent Prostate Cancer
Baratto, L., Duan, H., Hatami, N., Song, H., Davidzon, G., Franc, B., … Iagaru, A. (2020). PSMA-and GRPR-targeted PET: Preliminary Results in Patients with Biochemically Recurrent Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
SUV measurements from images reconstructed with the block sequential regularized expectation maximization algorithm: comparison of motion corrected vs. non-motion corrected data
Leonard, Z., Ramos, K., Nguyen, V., Castaneda, P., & Iagaru, A. (2020). SUV measurements from images reconstructed with the block sequential regularized expectation maximization algorithm: comparison of motion corrected vs. non-motion corrected data. JOURNAL OF NUCLEAR MEDICINE, 61. -
Ga-68-PSMA-11 PET/MR Imaging before prostatectomy: correlation with surgical pathology and two-year follow up
Moradi, F., Baratto, L., Duan, H., Hatami, N., Davidzon, G., Sonn, G., & Iagaru, A. (2020). Ga-68-PSMA-11 PET/MR Imaging before prostatectomy: correlation with surgical pathology and two-year follow up. JOURNAL OF NUCLEAR MEDICINE, 61. -
Determining optimal uptake time for Ga-68-labeled radiopharmaceuticals targeting gastrin-releasing peptide receptors with a modified NEMA phantom.
Ramos, K., Ferri, V., Baratto, L., Duan, H., & Iagaru, A. (2020). Determining optimal uptake time for Ga-68-labeled radiopharmaceuticals targeting gastrin-releasing peptide receptors with a modified NEMA phantom. JOURNAL OF NUCLEAR MEDICINE, 61. -
Diagnostic Performance of PSMA-Targeted F-18-DCFPyL PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the Phase 3, Multicenter CONDOR Study
Rowe, S., Gorin, M., Saperstein, L., Pouliot, F., Josephson, D., Carroll, P., … Siegel, B. (2020). Diagnostic Performance of PSMA-Targeted F-18-DCFPyL PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the Phase 3, Multicenter CONDOR Study. JOURNAL OF NUCLEAR MEDICINE, 61. -
Ga-68-RM2 PET/CT in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer
Baratto, L., Duan, H., Hatami, N., Aparici, C. M., Davidzon, G., & Iagaru, A. (2020). Ga-68-RM2 PET/CT in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE, 61. -
Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6 Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy.
Natarajan, A., Srinivas, S. M., Azevedo, C., Greene, L., Bauchet, A.-L., Jouannot, E., … Gambhir, S. S. (2020). Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6 Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy. Molecular Imaging, 19, 1536012120939398. -
Letter to the Editor: "Disparities in PET imaging for prostate cancer at a tertiary academic medical center".
Franc, B. L., & Iagaru, A. (2020). Letter to the Editor: "Disparities in PET imaging for prostate cancer at a tertiary academic medical center". Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
OBITUARY Sanjiv "Sam" Gambhir, MD, PhD: In Memoriam (1962-2020)
Wu, A. M., Iagaru, A., Herschman, H., Weissleder, R., & Sawyers, C. L. (2020). OBITUARY Sanjiv "Sam" Gambhir, MD, PhD: In Memoriam (1962-2020). CANCER RESEARCH, 80(20), 4305–6. -
Humana and 18F-FDG PET/CT: Another Sequel to the Injustice of Being Judged by the Errors of Others.
Czernin, J., & Iagaru, A. (2020). Humana and 18F-FDG PET/CT: Another Sequel to the Injustice of Being Judged by the Errors of Others. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A single institution experience in the USA
Duan, H., Ferri, V., Kunz, P. L., Fisher, G. A., Moradi, F., Davidzon, G. A., … Mari, C. A. (2020). Peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET): A single institution experience in the USA. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 47(SUPPL 1), S468–S469. -
Preliminary Results of F-18-FSPG PET/CT in Patients Referred for Exclusion of Active Cardiac Sarcoidosis after Non-Contributory F-18-FDG PET/CT
Iagaru, A., Duan, H., Baratto, L., Gambhir, S. S., & Witteles, R. (2020). Preliminary Results of F-18-FSPG PET/CT in Patients Referred for Exclusion of Active Cardiac Sarcoidosis after Non-Contributory F-18-FDG PET/CT. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 47(SUPPL 1), S391–S392. -
Evaluation of toxicity in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET)
Duan, H., Ferri, V., Kunz, P. L., Fisher, G. A., Moradi, F., Davidzon, G. A., … Mari, C. A. (2020). Evaluation of toxicity in peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NET). EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 47(SUPPL 1), S471–S472. -
Prospective Single Institution Study of F18-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: An Analysis of Lesions Detection and Localization
Iagaru, A., Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., … Davidzon, G. (2020). Prospective Single Institution Study of F18-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: An Analysis of Lesions Detection and Localization. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 47(SUPPL 1), S171. -
Humana and 18F-FDG PET/CT: Another Sequel to the Injustice of Being Judged by the Errors of Others.
Czernin, J., & Iagaru, A. (2021). Humana and 18F-FDG PET/CT: Another Sequel to the Injustice of Being Judged by the Errors of Others. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 62(1), 1–2. -
High quality imaging and dosimetry for yttrium-90 (90Y) liver radioembolization using a SiPM-based PET/CT scanner.
Duan, H., Khalaf, M. H., Ferri, V., Baratto, L., Srinivas, S. M., Sze, D. Y., & Iagaru, A. (2021). High quality imaging and dosimetry for yttrium-90 (90Y) liver radioembolization using a SiPM-based PET/CT scanner. European Journal of Nuclear Medicine and Molecular Imaging. -
18F-FDG PET/CT for Evaluation of Post-Transplant Lymphoproliferative Disorder (PTLD).
Song, H., Guja, K. E., & Iagaru, A. (2021). 18F-FDG PET/CT for Evaluation of Post-Transplant Lymphoproliferative Disorder (PTLD). Seminars in Nuclear Medicine. -
The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval.
Nakamoto, R., Harrison, C., Song, H., Guja, K. E., Hatami, N., Nguyen, J., … Iagaru, A. (2021). The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval. Molecular Imaging and Biology. -
Effect of CD47 Blockade on Vascular Inflammation.
Jarr, K.-U. U., Nakamoto, R., Doan, B. H., Kojima, Y., Weissman, I. L., Advani, R. H., … Leeper, N. J. (2021). Effect of CD47 Blockade on Vascular Inflammation. The New England Journal of Medicine, 384(4), 382–83. -
Molecular imaging of pancreatic neoplasms
Duan, H., Baratto, L., Laudicella, R., Stracuzzi, F., Baldari, S., & Iagaru, A. (2021). Molecular imaging of pancreatic neoplasms. CLINICAL AND TRANSLATIONAL IMAGING. -
Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.
Nakamoto, R., Zaba, L. C., Liang, T., Reddy, S. A., Davidzon, G., Aparici, C. M., … Franc, B. L. (2021). Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study.
Morris, M. J., Rowe, S. P., Gorin, M. A., Saperstein, L., Pouliot, F., Josephson, D. Y., … Pachynski, R. K. (2021). Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
A prospective study of Ga-68-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging.
Baratto, L., Song, H., Duan, H., Aparici, C. M., Davidzon, G., Moradi, F., … Iagaru, A. (2020). A prospective study of Ga-68-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buyyounouski, M., … Iagaru, A. (2021). PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
High-specific-activity 131I-MIBG vs 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma.
Jha, A., Taieb, D., Carrasquillo, J. A., Pryma, D. A., Patel, M., Millo, C., … Pacak, K. (2021). High-specific-activity 131I-MIBG vs 177Lu-DOTATATE targeted radionuclide therapy for metastatic pheochromocytoma and paraganglioma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
A single institution experience with peptide receptor radionuclide therapy (PRRT) in non-midgut neuroendocrine tumors (NETs)
Duan, H., Ferri, Fisher, G., Shaheen, S., Davidzon, G., Moradi, F., … Mari, A. C. (2021). A single institution experience with peptide receptor radionuclide therapy (PRRT) in non-midgut neuroendocrine tumors (NETs). JOURNAL OF NEUROENDOCRINOLOGY, 33, 181. -
A single institution experience with peptide receptor radionuclide therapy (PRRT) in advanced pheochromocytoma and paraganglioma
Duan, H., Ferri, Fisher, G., Shaheen, S., Davidzon, G., Moradi, F., … Mari, A. C. (2021). A single institution experience with peptide receptor radionuclide therapy (PRRT) in advanced pheochromocytoma and paraganglioma. JOURNAL OF NEUROENDOCRINOLOGY, 33, 180. -
Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas.
Laudicella, R., Quartuccio, N., Argiroffi, G., Alongi, P., Baratto, L., Califaretti, E., … Iagaru, A. (2021). Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas. European Journal of Nuclear Medicine and Molecular Imaging. -
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Pouliot, F., Gorin, M. A., Rowe, S. P., Saperstein, L., Josephson, D., Carroll, P. R., … Siegel, B. A. (2021). PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. JOURNAL OF CLINICAL ONCOLOGY, 39(6). -
Prognostic relevance of the hexosamine biosynthesis pathway activation in leiomyosarcoma.
Tolwani, A., Matusiak, M., Bui, N., Forgo, E., Varma, S., Baratto, L., … Przybyl, J. (2021). Prognostic relevance of the hexosamine biosynthesis pathway activation in leiomyosarcoma. NPJ Genomic Medicine, 6(1), 30. -
Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., … Aparici, C. M. (2021). Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience. PANCREAS, 50(3), 456–457. -
Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., … Aparici, C. M. (2021). Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET). PANCREAS, 50(3), 456. -
Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Moradi, F., Nguyen, J., … Aparici, C. M. (2021). Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience. PANCREAS, 50(3), 456. -
New PET technologies - embracing progress and pushing the limits.
Aide, N., Lasnon, C., Kesner, A., Levin, C. S., Buvat, I., Iagaru, A., … McGowan, D. R. (2021). New PET technologies - embracing progress and pushing the limits. European Journal of Nuclear Medicine and Molecular Imaging. -
Results of a Prospective Trial to Compare 68Ga-DOTA-TATE with SiPM-Based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors.
Baratto, L., Toriihara, A., Hatami, N., Aparici, C. M., Davidzon, G., Levin, C. S., & Iagaru, A. (2021). Results of a Prospective Trial to Compare 68Ga-DOTA-TATE with SiPM-Based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors. Diagnostics (Basel, Switzerland), 11(6). -
Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Moradi, F., Nguyen, J., … Aparici, C. M. (2021). Hematotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., … Aparici, C. M. (2021). Renal and Hepatotoxicity of Peptide Receptor Radionuclide Therapy (PRRT) - A Single Institution Experience. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET)
Duan, H., Ferri, V., Kunz, P., Davidzon, G., Nguyen, J., Moradi, F., … Aparici, C. M. (2021). Single Institution Experience With Peptide Receptor Radionuclide Therapy (PRRT) in Neuroendocrine Tumors (NET). PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW
Krishnan, G., van den Berg, N. S., Nishio, N., Juniper, G., Pei, J., Zhou, Q., … Rosenthal, E. L. (2021). Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW. THERANOSTICS, 11(15), 7188–7198. -
Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW.
Krishnan, G., van den Berg, N. S., Nishio, N., Juniper, G., Pei, J., Zhou, Q., … Rosenthal, E. L. (2021). Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW. Theranostics, 11(15), 7188–7198. -
2021 SNMMI Highlights Lecture: General Nuclear Medicine.
Iagaru, A. (2021). 2021 SNMMI Highlights Lecture: General Nuclear Medicine. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 62(8), 12N–17N. -
Clinical Applications of PET/MR Imaging.
Moradi, F., Iagaru, A., & McConathy, J. (2021). Clinical Applications of PET/MR Imaging. Radiologic Clinics of North America, 59(5), 853–874. -
Prostate cancer: Molecular imaging and MRI.
Moradi, F., Farolfi, A., Fanti, S., & Iagaru, A. (2021). Prostate cancer: Molecular imaging and MRI. European Journal of Radiology, 143, 109893. -
Reduced Acquisition Time Per Bed Position for PET/MRI Using 68Ga-RM2 or 68Ga-PSMA11 in Patients With Prostate Cancer: A Retrospective Analysis.
Duan, H., Baratto, L., Hatami, N., Liang, T., Levin, C. S., Khalighi, M. M., & Iagaru, A. (2021). Reduced Acquisition Time Per Bed Position for PET/MRI Using 68Ga-RM2 or 68Ga-PSMA11 in Patients With Prostate Cancer: A Retrospective Analysis. AJR. American Journal of Roentgenology. -
To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy.
Srinivas, S., & Iagaru, A. (2021). To Scan or Not to Scan: An Unnecessary Dilemma for PSMA Radioligand Therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Positron Emission Tomography (PET) Characterization for Biology-Guided Radiotherapy (BgRT)
Hu, Z., Narayanan, M., Ferri, V., Iagaru, A., Kovalchuk, N., Han, B., … Surucu, M. (2021). Positron Emission Tomography (PET) Characterization for Biology-Guided Radiotherapy (BgRT). MEDICAL PHYSICS. WILEY. -
A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2 Induced Glycolytic Reprogramming in Glioblastoma.
Beinat, C., Patel, C. B., Haywood, T., Murty, S., Naya, L., Castillo, J. B., … Gambhir, S. S. (2021). A Clinical PET Imaging Tracer ([18F]DASA-23) to Monitor Pyruvate Kinase M2 Induced Glycolytic Reprogramming in Glioblastoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Association of Time Since Administration of Pegylated G-CSF (Pegfilgrastim) and Bone Marrow Uptake on FDG PET/CT: Determination of a Minimum Interval.
Minamimoto, R., Baratto, L., & Iagaru, A. (2021). Association of Time Since Administration of Pegylated G-CSF (Pegfilgrastim) and Bone Marrow Uptake on FDG PET/CT: Determination of a Minimum Interval. AJR. American Journal of Roentgenology. -
18F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval.
Song, H., Iagaru, A., & Rowe, S. P. (2021). 18F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING
Baratto, L., Song, H., Duan, H., Moradi, F., Davidzon, G., & Iagaru, A. (2021). PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
PROSPECTIVE EVALUATION OF F-18-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF F-18-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES
Song, H., Nguyen, J., Moradi, F., Aparici, C. M., Franc, B., Davidzon, G., & Iagaru, A. (2021). PROSPECTIVE EVALUATION OF F-18-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF F-18-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES. JOURNAL OF UROLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Comparison of a First-in-Class LINAC-Integrated PET System and a Diagnostic PET/CT Scanner.
Surucu, M., Maniyedath, A., Narayanan, M., Han, B., Kovalchuk, N., Gensheimer, M. F., … Chang, D. T. (2021). Comparison of a First-in-Class LINAC-Integrated PET System and a Diagnostic PET/CT Scanner. International Journal of Radiation Oncology, Biology, Physics, 111(3S), e515–e516. -
Initial Evaluation of Biology-Guided Radiotherapy (BgRT) Plans Generated Using PET Acquired on the First Installation of New System.
Surucu, M., Narayanan, M., Han, B., Khan, S., Da Silva, A., Maniyedath, A., … Kovalchuk, N. (2021). Initial Evaluation of Biology-Guided Radiotherapy (BgRT) Plans Generated Using PET Acquired on the First Installation of New System. International Journal of Radiation Oncology, Biology, Physics, 111(3S), e516. -
Pilot-phase PET/CT study targeting integrin alphavbeta6 in pancreatic cancer patients using the cystine-knot peptide-based 18F-FP-R01-MG-F2.
Nakamoto, R., Ferri, V., Duan, H., Hatami, N., Goel, M., Rosenberg, J., … Gambhir, S. S. (2021). Pilot-phase PET/CT study targeting integrin alphavbeta6 in pancreatic cancer patients using the cystine-knot peptide-based 18F-FP-R01-MG-F2. European Journal of Nuclear Medicine and Molecular Imaging. -
2021 SNMMI Highlights Lecture: General Nuclear Medicine
Iagaru, A. (2021). 2021 SNMMI Highlights Lecture: General Nuclear Medicine. JOURNAL OF NUCLEAR MEDICINE, 62(8), 12N–17N. -
PSMA-targeted imaging with F-18-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.
Pouliot, F., Gorin, M. A., Rowe, S. P., Saperstein, L., Josephson, D., Carroll, P. R., … Siegel, B. A. (2021). PSMA-targeted imaging with F-18-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Comparison of a First-in-Class LINAC-Integrated PET System and a Diagnostic PET/CT Scanner
Surucu, M., Maniyedath, A., Narayanan, M., Han, B., Kovalchuk, N., Gensheimer, M. F., … Chang, D. T. (2021). Comparison of a First-in-Class LINAC-Integrated PET System and a Diagnostic PET/CT Scanner. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
Initial Evaluation of Biology-Guided Radiotherapy (BgRT) Plans Generated Using PET Acquired on the First Installation of New System
Surucu, M., Narayanan, M., Han, B., Khan, S., Da Silva, A., Maniyedath, A., … Kovalchuk, N. (2021). Initial Evaluation of Biology-Guided Radiotherapy (BgRT) Plans Generated Using PET Acquired on the First Installation of New System. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS. ELSEVIER SCIENCE INC. -
68Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors.
Duan, H., Baratto, L., Hatami, N., Liang, T., Mari Aparici, C., Davidzon, G. A., & Iagaru, A. (2021). 68Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors. Translational Oncology, 15(1), 101293. -
Initial Clinical Evaluation of [F-18]DASA-23, a PET Imaging Tracer for Evaluation of Aberrantly Expressed Pyruvate Kinase M2 in Glioblastoma
Beinat, C., Patel, C., Haywood, T., Naya, L., Castillo, J., Shen, B., … Gambhir, S. (2021). Initial Clinical Evaluation of [F-18]DASA-23, a PET Imaging Tracer for Evaluation of Aberrantly Expressed Pyruvate Kinase M2 in Glioblastoma. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
A Pilot Study of68Ga-PSMA11 PET/MRI and68GaRM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
Duan, H., Ferri, V., Ghanouni, P., Daniel, B., Hatami, N., Davidzon, G., … Iagaru, A. (2021). A Pilot Study of68Ga-PSMA11 PET/MRI and68GaRM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Pilot Comparison of F-18-FP-R01-MG-F2 and F-18-FDG PET in Patients with Pancreatic Cancer
Nakamoto, R., Duan, H., Ferri, V., Hatami, N., Goel, M., Kimura, R., … Iagaru, A. (2021). Pilot Comparison of F-18-FP-R01-MG-F2 and F-18-FDG PET in Patients with Pancreatic Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Biodistribution and Safety of F-18-FP-R(0)1-MG-F2 Knottin PET Tracer in Patients with Pancreatic Cancer
Nakamoto, R., Duan, H., Ferri, V., Hatami, N., Goel, M., Kimura, R., … Iagaru, A. (2021). Biodistribution and Safety of F-18-FP-R(0)1-MG-F2 Knottin PET Tracer in Patients with Pancreatic Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Perfusion Only Scans with and without SPECT/CT in the Era of COVID-19
Zhang, R., Moradi, F., Aparici, C. M., Davidzon, G., Nguyen, J., Iagaru, A., & Franc, B. (2021). Perfusion Only Scans with and without SPECT/CT in the Era of COVID-19. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
A Phase 3 study of F-18-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer (CONDOR): An Analysis of Disease Detection Rate and Positive Predictive Value (PPV) by Anatomic Region
Rowe, S., Gorin, M., Saperstein, L., Pouliot, F., Josephson, D., Carroll, P., … Siegel, B. (2021). A Phase 3 study of F-18-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer (CONDOR): An Analysis of Disease Detection Rate and Positive Predictive Value (PPV) by Anatomic Region. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging.
Duan, H., Iagaru, A., & Aparici, C. M. (1800). Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging. Nanotheranostics, 6(1), 103–117. -
Pilot phase study of F-18-FP-R(0)1-MG-F2 PET in pancreatic cancer patients
Nakamoto, R., Ferri, V., Duan, H., Hatami, N., Goel, M., Rosenberg, J., … Iagaru, A. (2021). Pilot phase study of F-18-FP-R(0)1-MG-F2 PET in pancreatic cancer patients. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
A Pilot Study of Ga-68-PSMA11 and Ga-68-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy
Duan, H., Ghanouni, P., Hatami, N., Davidzon, G. A., Aparici, C. M., Thong, A., … Iagaru, A. (2021). A Pilot Study of Ga-68-PSMA11 and Ga-68-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
Duan, H., Ferri, V., Ghanouni, P., Daniel, B., Hatami, N., Davidzon, G. A., … Iagaru, A. (2021). A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
Disparities in PET Imaging of Prostate Cancer at a Tertiary Academic Medical Center
Iagaru, A., & Franc, B. (2021). Disparities in PET Imaging of Prostate Cancer at a Tertiary Academic Medical Center. JOURNAL OF NUCLEAR MEDICINE, 62(5), 747–748. -
Correction to: Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas.
Laudicella, R., Quartuccio, N., Argiroffi, G., Alongi, P., Baratto, L., Califaretti, E., … Iagaru, A. (2022). Correction to: Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas. European Journal of Nuclear Medicine and Molecular Imaging. -
Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Iagaru, A., & Aparici, C. M. (2022). Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up. ONCOLOGIST. -
PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature.
Alongi, P., Laudicella, R., Lanzafame, H., Farolfi, A., Mapelli, P., Picchio, M., … Evangelista, L. (2022). PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature. Cancers, 14(7). -
Evaluation of interim Dotatate-PET after two cycles of Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors (NET)
Duan, H., Song, H., Ferri, Fisher, G., Shaheen, S., Shah, J., … Mari, A. C. (2022). Evaluation of interim Dotatate-PET after two cycles of Peptide Receptor Radionuclide Therapy (PRRT) in neuroendocrine tumors (NET). JOURNAL OF NEUROENDOCRINOLOGY. WILEY. -
68Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.
Moradi, F., Duan, H., Song, H., Davidzon, G. A., Chung, B. I., Thong, A. E., … Iagaru, A. (2022). 68Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Correlation of 68Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.
Duan, H., Baratto, L., Fan, R. E., Soerensen, S. J., Liang, T., Chung, B. I., … Iagaru, A. (2022). Correlation of 68Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up.
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Iagaru, A., & Mari Aparici, C. (2022). Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up. The Oncologist. -
PSMA theragnostics for metastatic castration resistant prostate cancer.
Song, H., Guja, K. E., & Iagaru, A. (2022). PSMA theragnostics for metastatic castration resistant prostate cancer. Translational Oncology, 22, 101438. -
Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience
Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Moradi, F., … Aparici, C. M. (2022). Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience. PANCREAS. LIPPINCOTT WILLIAMS & WILKINS. -
89Zr-panitumumab combined with 18F-FDG-PET improves detection and staging of head and neck squamous cell carcinoma.
Lee, Y.-J., van den Berg, N. S., Duan, H., Azevedo, E. C., Ferri, V., Hom, M., … Rosenthal, E. L. (2022). 89Zr-panitumumab combined with 18F-FDG-PET improves detection and staging of head and neck squamous cell carcinoma. Clinical Cancer Research : an Official Journal of the American Association for Cancer Research. -
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Haddad, R. I., Bischoff, L., Ball, D., Bernet, V., Blomain, E., Busaidy, N. L., … Darlow, S. (2022). Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN, 20(8), 925–951. -
The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer
Duan, H., & Iagaru, A. (2022). The use of advanced imaging in guiding the further investigation and treatment of primary prostate cancer. CANCER IMAGING, 22(1), 45. -
PET Imaging Using Gallium-68 (68Ga) RM2.
Duan, H., & Iagaru, A. (2022). PET Imaging Using Gallium-68 (68Ga) RM2. PET Clinics. -
Modified PROMISE Criteria for Standardized Interpretation of GRPR-targeted PET
Duan, H., Davidzon, G. A., Moradi, F., Liang, T., & Iagaru, A. (2022). Modified PROMISE Criteria for Standardized Interpretation of GRPR-targeted PET. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
Novel CZT-based multi detector SPECT/CT system: daily QCs and performance evaluation at one year after installation
Ferri, V., Luong, K., Castaneda, P., & Iagaru, A. (2022). Novel CZT-based multi detector SPECT/CT system: daily QCs and performance evaluation at one year after installation. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
A Pilot Study of Ga-68-PSMA11 and Ga-68-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Davidzon, G. A., Aparici, C. M., … Iagaru, A. (2022). A Pilot Study of Ga-68-PSMA11 and Ga-68-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
A Pilot Study of Ga-68-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Thong, A., Sonn, G. A., … Iagaru, A. (2022). A Pilot Study of Ga-68-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
TOF image enhancement of non-TOF PET scans using deep learning: a generalizability study
Mehranian, A., Wollenweber, S. D., Bradley, K. M., Walker, M. D., Huellner, M., Guerra, L., … McGowan, D. R. (2022). TOF image enhancement of non-TOF PET scans using deep learning: a generalizability study. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
Head-to-head Comparison of a Conventional or CZT-based SPECT/CT with a Next Generation Multidetector CZT-based SPECT/CT System
Duan, H., Ferri, V., Castaneda, P., Visser, T., Luong, K., Davidzon, G. A., … Iagaru, A. (2022). Head-to-head Comparison of a Conventional or CZT-based SPECT/CT with a Next Generation Multidetector CZT-based SPECT/CT System. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
Image-mode performance characterization of a positron emission tomography subsystem designed for Biology-guided radiotherapy (BgRT).
Hu, Z., Bieniosek, M., Ferri, V., Iagaru, A., Kovalchuk, N., Han, B., … Surucu, M. (2022). Image-mode performance characterization of a positron emission tomography subsystem designed for Biology-guided radiotherapy (BgRT). The British Journal of Radiology, 20220387. -
A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy.
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Davidzon, G. A., Mari Aparici, C., … Iagaru, A. (2022). A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Evaluation of Prostate Cancer Response to High Intensity Focused Ultrasound (HIFU) Therapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.
Eads, J. R., Catalano, P. J., Fisher, G. A., Rubin, D., Iagaru, A., Klimstra, D. S., … O'Dwyer, P. J. (2022). Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Overview and Recent Advances in 18F-FDG PET/CT for Evaluation of Pediatric Lymphoma
Guja, K. E., Nadel, H., & Iagaru, A. (2023). Overview and Recent Advances in 18F-FDG PET/CT for Evaluation of Pediatric Lymphoma. Seminars in Nuclear Medicine, 53(3). -
A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer.
Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Thong, A., Kunder, C., … Iagaru, A. (2022). A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Neuroendocrine Tumor Diagnosis: PET/MR Imaging.
Duan, H., & Iagaru, A. (2023). Neuroendocrine Tumor Diagnosis: PET/MR Imaging. PET Clinics. -
SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting.
Song, H., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., … Iagaru, A. (2023). SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting. European Journal of Nuclear Medicine and Molecular Imaging. -
2022 SNMMI Highlights Lecture: General Nuclear Medicine.
Iagaru, A. (2023). 2022 SNMMI Highlights Lecture: General Nuclear Medicine. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
ChatGPT in nuclear medicine and radiology: lights and shadows in the AI bionetwork
Laudicella, R., Davidzon, G. A., Dimos, N., Provenzano, G., Iagaru, A., & Bisdas, S. (2023). ChatGPT in nuclear medicine and radiology: lights and shadows in the AI bionetwork. CLINICAL AND TRANSLATIONAL IMAGING. -
Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET.
Duan, H., Davidzon, G. A., Moradi, F., Liang, T., Song, H., & Iagaru, A. (2023). Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET. European Journal of Nuclear Medicine and Molecular Imaging. -
PSMA PET for Detection of Recurrence.
Duan, H., & Iagaru, A. (2023). PSMA PET for Detection of Recurrence. Seminars in Nuclear Medicine. -
International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology.
Veit-Haibach, P., Ahlström, H., Boellaard, R., Delgado Bolton, R. C., Hesse, S., Hope, T., … Herrmann, K. (2023). International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology. European Journal of Nuclear Medicine and Molecular Imaging. -
International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology
Veit-Haibach, P., Ahlstrom, H., Boellaard, R., Delgado Bolton, R. C., Hesse, S., Hope, T., … Herrmann, K. (2023). International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. -
European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer.
Oprea-Lager, D.-E. E., MacLennan, S., Bjartell, A., Briganti, A., Burger, I. A., de Jong, I., … Fanti, S. (2023). European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer. European Urology. -
Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression free survival in patients with prostate cancer
Song, H., Sjostrand, K., Duan, H., Ferri, V., Aparici, C. M., Davidzon, G., … Iagaru, A. (2023). Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression free survival in patients with prostate cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Reply to Perera Molligoda Arachchige AS [1]
Laudicella, R., Davidzon, G. A., Dimos, N., Provenzano, G., Iagaru, A., & Bisdas, S. (2023). Reply to Perera Molligoda Arachchige AS [1]. CLINICAL AND TRANSLATIONAL IMAGING. -
Analysis of the Measured FDG Uptake from the First-in-Human Clinical Trial of Biology-Guided Radiotherapy.
Surucu, M., Vitzthum, L., Chang, D. T., Gensheimer, M. F., Kovalchuk, N., Han, B., … Garant, A. (2023). Analysis of the Measured FDG Uptake from the First-in-Human Clinical Trial of Biology-Guided Radiotherapy. International Journal of Radiation Oncology, Biology, Physics, 117(2S), e61–e62. -
Final Analysis of a Prospective, Single-center, Phase II/III Imaging Trial of<SUP>68</SUP>Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer
Duan, H., Moradi, F., Davidzon, G. A., Liang, T., Song, H., Loening, A., … Iagaru, A. (2023). Final Analysis of a Prospective, Single-center, Phase II/III Imaging Trial of68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
Modified PROMISE Criteria for Standardized Interpretation of Gastrin Releasing Peptide Receptor (GRPR)-targeted PET
Duan, H., Davidzon, G. A., Moradi, F., Liang, T., Song, H., & Iagaru, A. (2023). Modified PROMISE Criteria for Standardized Interpretation of Gastrin Releasing Peptide Receptor (GRPR)-targeted PET. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. SPRINGER. -
<SUP>89</SUP>Zr-DFO-girentuximab for PET imaging of solid tumors likely to express high levels of carbonic anhydrase IX.
Iagaru, A., Takalkar, A. M., Higgins, G. S., Kiser, J. W., Tauchmanova, L., Shah, S., … Crowley, J. R. (2023). 89Zr-DFO-girentuximab for PET imaging of solid tumors likely to express high levels of carbonic anhydrase IX. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [68Ga]Ga-RM2-A Head-to-Head Pilot Comparison with [68Ga]Ga-PSMA-11.
Fernandez, R., Soza-Ried, C., Iagaru, A., Stephens, A., Muller, A., Schieferstein, H., … Kramer, V. (2023). Imaging GRPr Expression in Metastatic Castration-Resistant Prostate Cancer with [68Ga]Ga-RM2-A Head-to-Head Pilot Comparison with [68Ga]Ga-PSMA-11. Cancers, 16(1). -
Modified PROMISE Criteria for Standardized Interpretation of Gastrin Releasing Peptide Receptor (GRPR)-targeted PET
Duan, H., Davidzon, G., Moradi, F., Liang, T., & Iagaru, A. (2023). Modified PROMISE Criteria for Standardized Interpretation of Gastrin Releasing Peptide Receptor (GRPR)-targeted PET. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Final Analysis of a Prospective, Single-center, Phase II/III Imaging Trial of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer
Duan, H., Moradi, F., Davidzon, G., Liang, T., & Iagaru, A. (2023). Final Analysis of a Prospective, Single-center, Phase II/III Imaging Trial of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Total and Anatomically Contextualized Quantitative 18F-DCFPyL PET at biochemical recurrence predicts subsequent biochemical progression free survival in prostate cancer patients
Song, H., Duan, H., Ferri, V., Na, S. J., Davidzon, G., Franc, B., … Iagaru, A. (2023). Total and Anatomically Contextualized Quantitative 18F-DCFPyL PET at biochemical recurrence predicts subsequent biochemical progression free survival in prostate cancer patients. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Assessment of the response of treatment with 18F-DCFPYL PET/CT in patients with prostate cancer
Na, S. J., Duan, H., Song, H., & Iagaru, A. (2023). Assessment of the response of treatment with 18F-DCFPYL PET/CT in patients with prostate cancer. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
A Case-Based Primer on FDG PET/CT for Imaging Cardiovascular Infections: Protocol, Interpretation, and Pitfalls.
Zhou, W., Moradi, F., Davidzon, G., Song, H., Grady, E., Nguyen, J., … Shah, J. (2023). A Case-Based Primer on FDG PET/CT for Imaging Cardiovascular Infections: Protocol, Interpretation, and Pitfalls. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Rapid dynamic reconstruction using list mode data for monitoring PET image quality accurately predicts final image noise and perceived quality
Moradi, F., Khalighi, M. M., Su, K.-H., Zhang, X., Wollenweber, S., Spangler-Bickell, M., … Iagaru, A. (2023). Rapid dynamic reconstruction using list mode data for monitoring PET image quality accurately predicts final image noise and perceived quality. JOURNAL OF NUCLEAR MEDICINE. SOC NUCLEAR MEDICINE INC. -
Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review.
Khessib, T., Jha, P., Davidzon, G. A., Iagaru, A., & Shah, J. (2024). Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review. Seminars in Nuclear Medicine. -
Reply to Perera Molligoda Arachchige AS [1]
Laudicella, R., Davidzon, G. A., Dimos, N., Provenzano, G., Iagaru, A., & Bisdas, S. (2024). Reply to Perera Molligoda Arachchige AS [1]. CLINICAL AND TRANSLATIONAL IMAGING, 12(1), 109–110. -
68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial.
Duan, H., Moradi, F., Davidzon, G. A., Liang, T., Song, H., Loening, A. M., … Iagaru, A. (2024). 68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial. The Lancet. Oncology. -
Molecular Imaging in Soft-tissue Sarcoma: Evolving Role of FDG PET.
Guja, K. E., Ganjoo, K. N., & Iagaru, A. (2024). Molecular Imaging in Soft-tissue Sarcoma: Evolving Role of FDG PET. Seminars in Nuclear Medicine. -
Guiding principles on the education and practice of theranostics.
Pascual, T. N., Paez, D., Iagaru, A., Gnanasegaran, G., Lee, S. T., Sathekge, M., … Scott, A. M. (2024). Guiding principles on the education and practice of theranostics. European Journal of Nuclear Medicine and Molecular Imaging. -
The Age of Theragnostics.
Iagaru, A., & Jacene, H. (2024). The Age of Theragnostics. PET Clinics. -
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Song, H., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., … Iagaru, A. (2024). Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
- 18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation »
- Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT »
- [177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake »
- Biodistribution&Pharmacokinetic of Position Emission Tomography(PET) Radiopharmaceutical 18F C SNAT4 »
- Comparison of PET/CT vs. PET/MRI Using 2 Radiopharmaceuticals »
- Standard PET/CT vs. Digital PET/CT »
- Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer »
- HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer »
- F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer »
- Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer »
- 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery »
- 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment »
Practice Locations
Nuclear Medicine and Molecular Imaging Stanford, CA
Stanford, CANuclear Medicine and Molecular Imaging
300 Pasteur Drive, 2nd Floor, C21
Stanford , CA 94305
Make An Appointment More Clinic Information » Getting Here »Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology orders
- View referral status
- Access medical records